Gilead Sciences - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Gilead Sciences
GILD
|
NASDAQ
|
United States
137
+57
Rank
$82.96B
Market Cap
$28.75B
+$ 1.64B
+6.05%
Revenue
$0.69B
-$ 6.16B
-89.93%
Earnings
17.6K
-0.4K
-2.22%
Employees
About
Gilead Sciences, Inc. (GILD)
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
- Sector: Health Technology
- Industry: Biotechnology
- Headquarters:
Latest News
-
Gilead Sciences Highlights Trodelvy Lung Data, Long-Acting HIV Pipeline at RBC Conference
24.05.2026 -
Is It Time To Reassess Gilead Sciences (GILD) After Strong Multi Year Share Price Gains
23.05.2026 -
Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
22.05.2026 -
Gilead Sciences completes Tubulis acquisition for $5bn
22.05.2026 -
Gilead Sciences Says CHMP Of EMA Adopts Positive Opinion, Recommending Marketing Authorization Of Trodelvy As Monotherapy For Treatment Of Adult Patients With Triple-Negative Breast Cancer; EU Decision Expected Later 2026
22.05.2026